<DOC>
	<DOCNO>NCT00721331</DOCNO>
	<brief_summary>This phase I , single center , randomize , vehicle-controlled , blind study compare two dosage strength CRx-197 cream , nortriptyline , active comparator ( 0.1 % mometasone ) placebo ( active ingredient free vehicle cream CRx-197 ) healthy volunteer .</brief_summary>
	<brief_title>A Phase I Study Assess Safety Tolerability Topical CRx-197 Formulations Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Nortriptyline</mesh_term>
	<criteria>Subject must voluntarily sign date write Informed Consent prior study specific procedure Subject must 18 60 year age Subject must healthy skin redden easily recognize area place test field Subject must free condition/disease investigator feel interfere interpretation study result . Females childbearing potential either surgically sterile ( hysterectomy tubal ligation ) , use highly effective medically accept contraceptive regimen . A highly effective method birth control define result lower failure rate ( i.e. , less 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , sexual abstinence vasectomise partner . Suntan , hyper hypopigmentation , tattoos area place test field Dark skin person whose skin color prevents ready assessment skin reaction Cardiac disease , include recent myocardial infarction , degree heart block cardiac arrhythmia valvular heart disease Mania Narrow angle glaucoma Hyperthyroidism medical history , TSH less LLN , subject receive thyroid medication Severe liver disease ALT laboratory value exceed 1.5x ULN Inflammatory dermatosis ( e.g. , atopic dermatoses/eczema , psoriasis ) Any skin condition involve test field include limited bacterial , viral , fungal skin infection , acne , rosacea Active varicella , tuberculosis , syphilis postvaccine reaction Autoimmune disease ( e.g. , lupus erythematosis ) Known allergic reaction hypersensitivity component study treatment Allergy adhesives patch use occlusion study UV therapy significant UV exposure four week treatment application History malignancy ( except treat excised basal cell carcinoma ) Surgery within previous 3 month ( except minor cosmetic dental procedure ) History drug alcohol abuse ( define Investigator ) Symptoms clinically significant illness four week treatment application may influence outcome study Positive HIV antibody Systemic treatment four week prior treatment application may interact study drug , : Glucocorticoids , MAO inhibitor , antidepressant , antiseizure medication , antipsychotic antihistamines Subjects require medication inhibit CYP450 2D6 pathway : Quinidine , Cimetidine , Type 1 antiarrhythmic , Phenothiazines , Selective serotonin reuptake inhibitor , Reserpine , anticholinergic drug , sympathomimetic drug Treatment investigational agent within one month treatment application trial Female subject pregnant , lactating , positive pregnancy test Unwilling unable comply requirement protocol , include presence condition ( physical , mental , social ) likely affect subject 's return followup visit schedule Other unspecified reason , opinion Investigator , make subject unsuitable enrollment Subject institutionalized legal regulatory order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>CombinatoRx</keyword>
	<keyword>Atopic</keyword>
	<keyword>Dermatitis</keyword>
	<keyword>Topical</keyword>
	<keyword>CRx-197</keyword>
	<keyword>Normal Healthy Volunteers</keyword>
</DOC>